Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium
Phase 2
Completed
- Conditions
- Infertility, FemaleInfertility
- Interventions
- Drug: Plasma rich in growth factors (PRGF-Endoret)
- Registration Number
- NCT03387501
- Lead Sponsor
- Sara Rafael Fernandez
- Brief Summary
This study evaluate the percentage of women with thin endometrium who achieve an endometrial thickness equal to or greater than 7 mm after administration of PRGF (plasma rich in growth factors)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 13
Inclusion Criteria
- Women who signed informed consent.
- Women who understand the Spanish language.
- Women under 42 years
Exclusion Criteria
- Thrombopenia.
- Congenital or acquired uterine malformations that reduce embryo implantation or term gestation.
- Ovarian tumors.
- Benign uterine tumors require surgical treatment
- Local acute inflammatory diseases
- Patients with malignant tumors requiring chemotherapy.
- Patients with acute or chronic infectious or inflammatory diseases requiring active treatment with drugs that may interfere with implantation and gestation.
- Chronic treatment with NSAIDs (Nonsteroidal anti-inflammatory drugs)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description PRGF Plasma rich in growth factors (PRGF-Endoret) Plasma rich in growth factors (PRGF) administration
- Primary Outcome Measures
Name Time Method Percentage of women who achieve an endometrial thickness equal to or greater than 7 mm 3 days after administration of PRGF Measurement of the endometrial thickness by ultrasonography.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hospital Clinico San Carlos
🇪🇸Madrid, Spain